Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?

ABSTRACT:

Importance

Recent changes in guidelines for managing Clostridioides difficile infections (CDI) have placed fidaxomicin as a first-line treatment.

Objective

To estimate the net cost of first-line fidaxomicin compared to vancomycin in the American and Canadian healthcare systems and to estimate the price points at which fidaxomicin would become cost saving for the prevention of recurrence.

Data sources and study selection

We identified randomized, placebo-controlled trials directly comparing fidaxomicin with vancomycin that reported on recurrence. Medication costs were obtained from the Veterans Affairs Federal Supply Schedule (US) and the Quebec drug formulary (Canada). The average cost of a CDI recurrence was established through a systematic review for each cou

SUBMITTER: Patel D 

PROVIDER: S-EPMC9825808 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature